A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Sponsor: Millennium Pharmaceuticals, Inc.
A PHASE1 clinical study on Advanced Solid Neoplasm, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 16 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Apr 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Status: Completed → Active Not Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Apr 2018 [monthly]
Recruiting PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .